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Volume 51, Number 4 Abstracts 1071years) and 125women (mean age, 70.0 11.2 years; PNS).Womenwere
more likely to undergo treatment for critical limb ischemia (87.7% vs 77.7%;
P .028) and less likely to have treatment for claudication (12.3% vs 22.3%;
P  NS). Women were also more likely to undergo balloon angioplasty
(57.5% vs 68.9%; P  .043). However, men were more likely to have
coronary disease, history of coronary bypass grafting, and chronic renal
insufficiency. TransAtlantic Intersociety Consensus distribution, incidence
of smoking, and diabetes were equivalent in both sexes. When adjusted for
comorbidities, women had higher 24-month primary patency rates
(46.0% 6.1% vs 30.4% 5.9%; P .016) and limb salvage rates (87.5%
4.1% vs 82.9% 5.4%; P .041) than men for tibial lesions with concurrent
proximal disease. The difference in 24-month patency between women and
men was more pronounced for isolated tibial lesions (50.1% 10.1% vs
28.8%  10.4%; P  .002). Although the overall complication rates were
similar, women had comparatively higher rates of postoperative access site
thrombosis than men (8.9% vs 0.6%, P  .001).
Conclusions: Overall, endovascular interventions below the knee are
safe and effective in women and should be considered the first-line modality
for the management of critical tibial occlusive disease. However, further
investigation and development of technique to better fit the female anatomy
is necessary to improve the gender-related disparity in access site-related
complications.
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Objective: Minimally invasive endovascular and percutaneous meth-
ods are now available for the management of visceral artery aneurysms and
pseudoaneurysms. This study reviewed our 10-year experience with the
minimally invasive treatment of visceral artery aneurysms.
Methods: The review included all patients evaluated from June 1999
to June 2009 with the diagnosis of aneurysms of the celiac, superior
mesenteric, and inferior mesenteric arteries and their branches. Medical
records were reviewed for demographics, therapy, and results.
Results: Minimally invasive management was attempted in 185
aneurysms in 176 patients (56% men; mean age, 58 years). Intervention
was successful in 182 of 185 (98%) aneurysms in 173 patients. Sixty-three
(34%) aneurysms were located in the splenic artery, 56 (30%) in the
hepatic artery, 28 (15%) in the gastroduodenal, 16 (8.6%) in the pancre-
aticoduodenal, 6 (3.2%) in the superior mesenteric, 4 (2.1%) in the
gastric, 4 (2.1%) in the celiac, 4 (2.1%) in the gastroepiploic, 2 (1%) in the
inferior mesenteric, and 1 (0.5%) in the middle colic artery. Pseudoan-
eurysms were more common than true aneurysms (64% vs 36%). Acute
bleeding was the indication for intervention in 86 aneurysms (46%).
Initial treatment was successful in 177 aneurysms (96%). Five aneurysms
(3%) required additional intervention 30 days for persistent flow or
bleeding. Coiling was the sole technique used in 139 aneurysms (75%)
and was combined with at least one other technique in 20 other aneu-
rysms (11%). Thirty-day aneurysm-related mortality was 1% (2 deaths).
Nine (4.8%) additional deaths occurred during the 30-day follow-up, but
none were related to complications of the aneurysms.
Conclusions: Minimally invasive intervention for visceral artery aneu-
rysms can be used alone or in combination to effectively treat these aneu-
rysms in elective or emergency conditions.
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Objective: Open bypass is the gold standard treatment for mesenteric
ischemia.With the refinement of endovascular therapy, visceral stenting is an
attractive minimally invasive alternative but has limited data, and which
vessel(s) respond best to stenting has not been addressed. This study
compared the outcomes of superior mesenteric artery (SMA) and celiac
artery (CA) stenting.Methods: All consecutive patients who received visceral stenting
between January 2002 and May 2009 were reviewed. Standard statisticalanalysis, including Kaplan-Meier, was performed. Primary patency was
defined as a peak systolic velocity350 cm/s for the CA and450 cm/s
for the SMA. A stenosis of50% at arteriography was considered a loss of
primary patency.
Results: Visceral stents were placed in 140 patients: SMA in 92
(65.7%), CA in 40 (28.6%), and inferior mesenteric artery in 8 (5.7%). There
were 29men (20.7%) and 111 women (79.3%) with amean age of 72.9 years
(range, 20.5-93.9 years). Mean follow-up was 12.8 months. Technical
success was 100% for all. The 30-day mortality rate was 0% for the SMA and
5% for the CA. One-year primary patency was 55% for the SMA and 17% for
the CA (P  .0001). Loss of CA primary patency was associated with
ischemic heart disease (P .05), stent diameter of6 mm (P .042), and
age 50 years (P  .038). These factors did not correlate with loss of
primary patency for the SMA (Fig).
Conclusions: Visceral stenting has an exceptional technical success
rate, with low procedural mortality. Primary patency of the SMA group
was significantly higher than that for the CA. Our data suggest that CA
stenosis, especially in young patients and those with small vessels, does
not respond well to stenting. Therefore, the practice of celiac artery
stenting should be abandoned.
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Objective: Endovascular interventions for symptomatic renal artery
stenosis have become the first-line treatment. Limited data are available for
the long-term outcome of secondary interventions of recurrent renal artery
stenosis after stenting.
Methods:This was a retrospective analysis of a 10-year experience with
percutaneous renal artery interventions. Only patients presenting with re-
current symptomatic stenosis were reviewed. End points analyzed included
freedom from tertiary procedures, a decrease in baseline renal function
20%, patency confirmed by duplex imaging, freedom from hemodialysis,
and patient survival.
Results: The review included 948 patients with 1150 renal arteries
treated; of these, 123 arteries in 108 patients (68.9% women) presented with
symptomatic recurrent stenosis, comprising recurrent hypertension in 97%
and renal insufficiency in 67%. The average age was 68.9. Mean follow-up
was 30 months (range, 1.2-104.7 months) for patency and 56 months
(range, 6.2-112.7 months) for creatinine level. Secondary interventions
included percutaneous transluminal angioplasty (PTA) only in 27, PTAwith
cutting balloon in 9, repeat renal artery stenting in 80, and drug-eluting
stent (DES) placement in 7. After secondary interventions, 20 of the 123
arteries (16.3%) in 18 patients required tertiary interventions. Freedom from
tertiary interventions was similar among treatment modalities, with PTA,
PTA-cutting balloon, stent, and DES groups having 81.5%, 100%, 83.8%,
and 71.4%, respectively, of patients remaining procedure free. Forty patients
(37%) had a decrease in renal function 20%, and 24 (22.2%) remained or
Fig.progressed to renal failure (estimated glomerular filtration rate 30%), and
eight ultimately required hemodialysis. Patient survival was 72.8% at 5 years.
